Advances in nanomedicine for the treatment of Alzheimer’s and Parkinson’s diseases

Written by Sara Hernando, Oihane Gartziandia, Enara Herran, Jose Luis Pedraz, Manoli Igartua & Rosa Maria Hernandez

Alzheimer‘s disease and Parkinson’s disease are the most common neurodegenerative diseases worldwide. Despite all the efforts made by the scientific community, current available treatments have limited effectiveness, without halting the progression of the disease. That is why, new molecules such as growth factors, antioxidants and metal chelators have been raised as new therapeutical approaches. However, these molecules have difficulties to cross the blood–brain barrier limiting its therapeutic effect. The development of nanometric drug delivery systems may permit a targeted and sustained release of old and new treatments offering a novel strategy to treat these neurodegenerative disorders. This review summarized the...

To view the full article, please register now for access

It's completely free